Shahram Paydar: TXA in Elderly Trauma: A Game-Changer for Endothelial Protection?
Shahram Paydar, Professor of Surgery and Trauma Surgeon, Consultant at Gulf Specialized Hospital, shared on LinkedIn:
“TXA in Elderly Trauma: A Game-Changer for Endothelial Protection? New Evidence Says Yes!
Trauma doesn’t discriminate by age, but outcomes do—especially for our older adults, who make up nearly 25% of admissions yet face steeper morbidity and mortality. Enter tranexamic acid (TXA): We know it’s a staple for bleeding control in TBI and hemorrhage, but a fresh 2025 analysis in J Trauma Acute Care Surg spotlights its extra punch in the ≥55 crowd.
Key findings from this secondary dive into the prehospital TXA-in-TBI database (n=436):
Despite similar injury severity (ISS ~20, head AIS ~3), older patients (mean 66y) showed sky-high admission endothelial biomarkers—thrombomodulin (↑17%), VCAM-1 (↑19%), angiotensin-2 (↑23%)—signaling pre-injury vulnerability.
The kicker?
2g prehospital TXA dampened these markers more dramatically in elders vs. younger folks (e.g., thrombomodulin p<0.00001, VCAM-1 p<0.0002 vs. placebo).
Younger subsets?
Less impact.
Why does this matter?
Endothelial dysfunction fuels the post-trauma inflammatory storm, and elders start from a weaker baseline. TXA’s amplified endothelial “shield” here could blunt hypercoagulability, reduce secondary hits, and—potentially—tip the scales on survival and recovery.
No direct mortality links yet (Level IV evidence), but it’s a clarion call: Standard TXA protocols might pack bigger benefits for our aging trauma wave.
As populations gray, this underscores TXA’s role beyond hemostasis—it’s endothelial insurance for the vulnerable.
Time to tweak protocols? Or wait for RCTs?
What’s your take—ramping up TXA emphasis in elder polytrauma? Share protocols or cases below!”
Title: Age matters: A Secondary Analysis of Endothelial Biomarkers in the Prehospital Tranexamic Acid for Traumatic Brain Injury Trial
Authors: Tanya Anand, Scott McLoud, Lindsay Loss, Karen Minoza, Phillip Jenkins, Susan Rowell, Jack McLean, Bellal Joseph, Martin Schreiber
Read the full article here.
Stay updated with Hemostasis Today.
-
Mar 12, 2026, 20:44Honoring Marion Stolte’s Lasting Impact on the Bleeding Disorders Community – WFH
-
Mar 12, 2026, 20:37Paul Riley: Is Thrombin Generation Assay Ready for Prime Time?
-
Mar 12, 2026, 20:28Rob Maloney: Building Visibility for Bleeding Disorders in Rural Georgia
-
Mar 12, 2026, 20:19Akshat Jain: Validating Oral Pain Medication Use as a Global Marker in Sickle Cell Disease
-
Mar 12, 2026, 20:13Michael Makris: Early Clinical Results of AAV8-BDD FVIII Gene Therapy in Hemophilia A
-
Mar 12, 2026, 20:02Wolfgang Miesbach: From Heparin to Vaccines – The Expanding Biology of Anti-PF4 Immunothrombosis
-
Mar 12, 2026, 19:56Christophe Dubois: Celebrating Nicolas Gendron’s HDR Defense and Future in Hemostasis
-
Mar 12, 2026, 17:06Caitlin Raymond: Managing Crigler–Najjar Syndrome Type 1 Crisis Without a Standard TPE Protocol
-
Mar 12, 2026, 17:03Jan Sloves: Insights on Comprehensive Venous Duplex Imaging at VEITH Symposium 2025